Open AccessKeratolysis exfoliativa-like eruption induced by ranolazine
Author(s) -
Elena Pierobon,
Lerica Germi,
Andrea Sechi,
Giampaolo Trevisan,
Elena Pezzolo,
Claudio Feliciani,
Debabrata Bandyopadhyay
Publication year - 2022
Publication title -
dermatology reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.183
H-Index - 10
eISSN - 2036-7406
pISSN - 2036-7392
DOI - 10.4081/dr.2022.9264
Subject(s) - medicine , ranolazine , desquamation , dermatology , drug eruption , drug , pharmacology
Dermatoses affecting palms may represent a dermatologic challenge from both the diagnostic, and therapeutic point of view. Patients with supposedly occupational dermatitis can spend months or even years in a frustrating attempt to avoid contact with possible irritants or allergens. To underline the importance of a thorough unbiased analysis of the patient’s history and clinical features, we present the iconic case of a bricklayer affected by a chronic, disabling desquamation of palms which in the end was classified as keratolysis exfoliativa (KE) attributed to ranolazine-intake, an antianginal drug. To the best of our knowledge, this specific adverse effect of druginduced KE of palms has never been reported before in association with ranolazine.